🌟 The TherVacB consortium congratulates our Coordinator Prof. @ulrike-protzer.bsky.social, awarded the German Medical Award 2025 as Female Doctor of the Year!

Her work drives #TherVacB and advances new hope for curing #HepatitisB through innovative research and European teamwork.

#WomenInScience

🎖️ The TherVacB consortium warmly congratulates our Coordinator Prof. @ulrike-protzer.bsky.social on receiving the German Federal Cross of Merit. Her pioneering #HepB research and leadership in developing the #TherVacB therapeutic vaccine advance the mission toward a functional cure.

#EUResearch

Prof. Ulrike Protzer receives Bundesverdienstkreuz

🎖️ Prof. Ulrike Protzer receives the “Bundesverdienstkreuz” (Federal Cross of Merit) in recognition of her outstanding contributions to the field of virology.

👉 Read more in our news: t1p.de/gkjvc

@ulrike-protzer.bsky.social @tum.de

#Virology #TherVacB #HepatitisB

🎉 The #TherVacB Project is now on LinkedIn! Follow us: www.linkedin.com/company/ther...

🧵Our 1st post sets the scene: the global challenge of chronic #HepatitisB and our goal of a #therapeutic #vaccine: tinyurl.com/TherVacB-Lin...

#HBV #H2020 #HealthInnovation #TherVacB #HepSky #LiverSky

Chronische Hepatitis B: Erster Patient erhält therapeutischen Impfstoff - DZG – Deutsche Zentren der Gesundheitsforschung TherVacB, ein unter der Leitung von Helmholtz Munich in Zusammenarbeit mit dem Deutschen Zentrum für Infektionsforschung (DZIF) neu entwickelter therapeutischer Impfstoff gegen chronische Hepatitis B,...

🏥 #TherVacB, ein neu entwickelter therapeutischer Impfstoff gegen chronische #HepatitisB, kommt erstmals in einer klinischen Studie an Patient:innen zum Einsatz. Im Juni 2025 wurde der erste Patient mit dem Impfstoff behandelt. @thervacb-eu.bsky.social

#Stigma can’t be cured with medicine. But it can be changed with knowledge. Research like this helps make #hepatitis care more inclusive and responsive.

🧩 Let’s break it down together.

#WHD2025 #HBV #TherVacB #PublicHealth #HealthSky @euonehealth.bsky.social @jmirpub.bsky.social

Most social science on #hepatitisB #stigma comes from Asia or Africa. 🌍
This study by the #TherVacB team (@ihemtum.bsky.social) & #clinical centres in Munich, Hannover & Leipzig fills a gap in Europe 🇪🇺.
✍Authors: Zimmermann, Willem, Rost, Matthes & Buyx

#EthicsInResearch #HealthEthics #HealthSky

What shapes stigma for people living with hepatitis B in Germany?
✅ Higher stigma: non-German mother tongue, high privacy needs, secrecy
❌ No link: age, gender, education
Culture & communication matter

#HealthEquity #HepCantWait #HBV #hepB #TherVacB @theresawillem.bsky.social @ihemtum.bsky.social

Perceptions of Stigma Among Patients With Hepatitis B in Germany: Cross-Sectional Survey Background: Many studies find associations between hepatitis B and stigma, but studies from the Western European context are lacking. Based on available studies, we hypothesized that younger age, high...

📘 New research from #TherVacB asks: How do people in Germany 🇩🇪 experience hepatitis B–related stigma?
💡A study with 195 participants offers insight into how language, privacy & disclosure affect perceptions of #stigma.

🔗 Read more: formative.jmir.org/2025/1/e66379/

#WHD2025 #HBV #PublicHealth

TherVacB & D-Solve unterstützen den Welt-Hepatitis-Tag 2025 mit ihrer Kampagne „Aufklärung über HDV und HBV“ Gut informiert, besser geschützt mit unserer Kampagne „Aufklärung über HDV und HBV“ - alles, was Sie über Hepatitis D und B wissen sollten

💡 Sie suchen fundierte Informationen zu #HepatitisB & #HepatitisD?
Die Kampagne „Aufklärung zu #HDV & #HBV“ von #TherVacB & #DSOLVE erklärt Co-Infektion, Diagnose und Therapie in Videos mit Expertinnen & Patientenperspektiven⚕️

📺 Zur Videoreihe: tinyurl.com/HepatitisBDW...

#WHT2025 #HepSky

World Hepatitis Day 2025 with Ongoing Awareness Campaign “Insights on HDV and HBV” Stay informed, stay protected with our campaign “Insights on HDV and HBV” – everything you need to know about hepatitis D and B.

💡 Looking for trusted info on #HepatitisB & #HepatitisD?

The #TherVacB & #DSOLVE video campaign “Insights on #HDV & #HBV” explains co-infection, diagnosis & treatment in expert-led, patient-focused videos⚕️

📺 Explore the full resource: tinyurl.com/HepatitisBDInsights

#WHD2025 #LiverSky

🧪 #TherVacB, a novel therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. This major milestone has been reached by DZIF scientists at @www.helmholtz-munich.de, @tum.de and @lmumuenchen.bsky.social. 🏥

👉 www.dzif.de/en/therapeut... 👉 @thervacb-eu.bsky.social

Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients

Fighting #HepatitisB

#TherVacB, a new therapeutic vaccine for chronic hepatitis B from #HelmholtzMunich, starts phase 1b/2a trial in patients. It aims to boost the immune system to eliminate the virus.

👉 t1p.de/qcncm

@lmu-klinikum.bsky.social @tum.de @ulrike-protzer.bsky.social

Start der klinischen Studie zur Entwicklung einer kurativen Strategie gegen chronische Hepatitis B Das TherVacB-Projekt, eine europäische Forschungsinitiative, hat mit dem Beginn der klinischen Studie an Patientinnen und Patienten einen bedeutenden Meilenstein erreicht

🧬 Zum #WeltHepatitisTag2025: Das EU-Projekt #TherVacB startet seine klinische Studie für eine kurative Immuntherapie gegen chronische #Hepatitis B.
🥼81 Patient*innen in Europa + Tansania
🎯1 Ziel: funktionelle Heilung
👉 tinyurl.com/TherVacBStudie
#LassUnsKlartextReden #LiverHealth #LiverSky #HepSky

A therapeutic vaccine to cure Hepatitis B - TherVacB Research project to cure Hepatitis B patients under the European Horizon 2020 programme using a newly designed vaccine in a clinical trial starting in 2024

🧬 On the road to #WorldHepatitisDay 2025, the EU project #TherVacB begins its clinical trial for a curative immune-based strategy against chronic #hepatitisB.
🔬81 patients across Europe + Tanzania
🎯1 goal: functional cure
👉 tinyurl.com/TherVacBtrial
#HepatitisCantWait #LiverHealth #LiverSky #HepSky